Evozyne Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 54

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $81M

  • Investors
  • 8

Evozyne General Information

Description

Operator of a data-driven evolution-based molecular engineering platform intended to create novel proteins with advanced functionality. The company's platform offers generative AI-driven design, experimental validation, iterative machine-learning refinement, and deep biological performance datasets, enabling pharmaceutical and biotechnology researchers to explore protein mechanisms, accelerate therapeutic discovery, and develop biologic treatments with enhanced specificity, stability and clinical potential.

Contact Information

Website
www.evozyne.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2430 North Halsted Street
  • Chicago, IL 60614
  • United States
+1 (312)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Healthcare Technology Systems
Corporate Office
  • 2430 North Halsted Street
  • Chicago, IL 60614
  • United States
+1 (312)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Evozyne Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 27-Sep-2023 $81M Completed Generating Revenue
3. Early Stage VC (Series A) 21-Apr-2021 Completed Generating Revenue
2. Accelerator/Incubator Completed Startup
1. University Spin-Out 01-Jan-2019 Completed Startup
To view Evozyne’s complete valuation and funding history, request access »

Evozyne Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Evozyne’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Evozyne Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a data-driven evolution-based molecular engineering platform intended to create novel proteins with advanced
Biotechnology
Chicago, IL
54 As of 2026

Toronto, Canada
 

Seattle, WA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Evozyne Competitors (38)

One of Evozyne’s 38 competitors is Deep Genomics, a Venture Capital-Backed company based in Toronto, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Deep Genomics Venture Capital-Backed Toronto, Canada
A-Alpha Bio Venture Capital-Backed Seattle, WA
AbCellera Biologics Formerly VC-backed Vancouver, Canada
GlycosBio Venture Capital-Backed Houston, TX
BellBrook Labs Venture Capital-Backed Madison, WI
You’re viewing 5 of 38 competitors. Get the full list »

Evozyne Patents

Evozyne Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4649492-A1 Artificial intelligence (ai)-based protein engineering systems and methods for designing synthetic protein sequences Pending 11-Jan-2023
US-20260221231-A1 Artificial intelligence (ai)-based protein engineering systems and methods for designing synthetic protein sequences Pending 11-Jan-2023
WO-2024151579-A1 Artificial intelligence (ai)-based protein engineering systems and methods for designing synthetic protein sequences Inactive 11-Jan-2023 G16B40/30

Evozyne Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Evozyne Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
In-Q-Tel Not-For-Profit Venture Capital Minority
NVentures (Santa Clara) Corporate Venture Capital Minority
NVIDIA Corporation Minority
OrbiMed Growth/Expansion Minority
Valor Equity Partners Growth/Expansion Minority
You’re viewing 5 of 8 investors. Get the full list »

Evozyne FAQs

  • When was Evozyne founded?

    Evozyne was founded in 2019.

  • Where is Evozyne headquartered?

    Evozyne is headquartered in Chicago, IL.

  • What is the size of Evozyne?

    Evozyne has 54 total employees.

  • What industry is Evozyne in?

    Evozyne’s primary industry is Biotechnology.

  • Is Evozyne a private or public company?

    Evozyne is a Private company.

  • What is the current valuation of Evozyne?

    The current valuation of Evozyne is .

  • What is Evozyne’s current revenue?

    The current revenue for Evozyne is .

  • How much funding has Evozyne raised over time?

    Evozyne has raised $135M.

  • Who are Evozyne’s investors?

    In-Q-Tel, NVentures (Santa Clara), NVIDIA, OrbiMed, and Valor Equity Partners are 5 of 8 investors who have invested in Evozyne.

  • Who are Evozyne’s competitors?

    Deep Genomics, A-Alpha Bio, AbCellera Biologics, GlycosBio, and BellBrook Labs are some of the 38 competitors of Evozyne.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process